Cell Motility and Cytoskeletal Regulation in Invasion and Metastasis

Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996;84(3):359–69.

Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127(4):679–95.

Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev 2004;4(6):448–56.

Schneider IC, Haugh JM. Mechanisms of gradient sensing and chemotaxis: conserved pathways, diverse regulation. Cell Cycle 2006;5(11):1130–4.

Dormann D, Weijer CJ. Chemotactic cell movement during development. Curr Opin Genet Dev 2003;13(4):358–64.

Mailleux AA, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N, et al. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development 2002;129(1):53–60.

Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev 2004;4(1):71–8

Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124(2):263–6.

Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172(7):973–81.

Nieto MA. The early steps of neural crest development. Mech Dev 2001;105(1–2):27–35.

Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N. Molecular pathways regulating EGF-induced epithelio–mesenchymal transition in human ovarian surface epithelium. Am J Physiol 2006 Jun;290(6):C1532–42.

Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004;16(1):14–23.

Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev 2003;3(12):921–30.

Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005;42(7):799–809.

Cupedo T, Mebius RE. Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin Immunol 2003;15(5):243–8.

Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354(6):610–21.

Zlotnik A. Chemokines and cancer. Int J Cancer 2006;119(9):2026–9.

Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 2006;60(6):273–6.

Smith MCP, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Philadelphia, A: American Association for Cancer Research; 2004. p. 8604–12.

Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003;5(5):R144–50.

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410(6824):50–6.

Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167(12):1676–86.

Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006;V25(3):357–71.

Holland JD, Kochetkova M, Akekawatchai C, Dottore M, Lopez A, McColl SR. Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 2006;66(8):4117–24.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366(1):2–16.

Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molec Cell 2003;11(2):495–505.

Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100(15):8933–8.

Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284(1):54–65.

Riese DJ II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20(1):41–8.

Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 1995;19(3):183–232.

Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003;1(3):165–75.

Stove C, Bracke M. Roles for neuregulins in human cancer. Clin Exp Metastasis 2004;21(8):665–84.

Willmarth NE, Ethier SP. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 2006;281(49):37728–37.

Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006;66(1):192–7.

Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004;64(19):7022–9.

Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H, et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 2006;66(3):1418–26.

Longati P, Comoglio PM, Bardelli A. Receptor tyrosine kinases as therapeutic targets the model of the MET oncogene. Current Drug Targets 2001;2:41–55.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915–25.

Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22(4):309–25.

Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006;238(1):30–41.

Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107(5):1761–7.

Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006;126(3):489–502.

Micke P, Ostman A. Tumour–stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45 Suppl 2:S163–75.

Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003;190(1):105–12.

Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65(12):5278–83.

Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004;64:8585–94.

Goswami S, Wang W, Wyckoff JB, Condeelis JS. Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy. Cancer Res 2004;64(21):7664–7.

Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003;112(4):453–65.

Mouneimne G, Soon L, DesMarais V, Sidani M, Song X, Yip SC, et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol 2004;166(5):697–708.

Yin HL, Janmey PA. Phosphoinositide regulation of the actin cytoskeleton. Annu Rev Physiol 2003;65:761–89.

Hurley JH. Membrane binding domains. Biochim Biophys Acta Mol Cell Biol Lipids 2006;1761(8):805–11.

van Rheenen J, Jalink K. Agonist-induced PIP(2) hydrolysis inhibits cortical actin dynamics: regulation at a global but not at a micrometer scale. Mol Biol Cell 2002;13(9):3257–67.

van Rheenen J, Achame EM, Janssen H, Calafat J, Jalink K. PIP2 signaling in lipid domains: a critical re-evaluation. EMBO J 2005;24(9):1664–73.

Franca-Koh J, Kamimura Y, Devreotes P. Navigating signaling networks: chemotaxis in Dictyostelium discoideum. Curr Opin Genet Dev 2006;16(4):333–8.

Barber MA, Welch HCE. PI3K and RAC signalling in leukocyte and cancer cell migration. Bull Cancer 2006;93(5):E44–52.

Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005;33:891–5.

Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS. Cofilin promotes actin polymerization and defines the direction of cell motility. Science 2004;304(5671):743–6.

Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007;1773(5):642–52.

Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A, et al. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol 2006;173(3):395–404.

Mouneimne G, DesMarais V, Sidani M, Scemes E, Wang W, Song X, et al. Spatial and temporal control of cofilin activity is required for directional sensing during chemotaxis. Curr Biol 2006;16(22):2193–205.

Takenawa T, Suetsugu S. The WASP–WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 2007;8(1):37–48.

Ichetovkin I, Grant W, Condeelis J. Cofilin produces newly polymerized actin filaments that are preferred for dendritic nucleation by the Arp2/3 complex. Curr Biol 2002;12(1):79–84.

Kurisu S, Suetsugu S, Yamazaki D, Yamaguchi H, Takenawa T. Rac–WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene 2004;24(8):1309–19.

Yamazaki D, Suetsugu S, Miki H, Kataoka Y, Nishikawa S-I, Fujiwara T, et al. WAVE2 is required for directed cell migration and cardiovascular development. Nature 2003;424(6947):452–6.

Kovar DR. Molecular details of formin-mediated actin assembly. Curr Opin Cell Biol 2006;18(1):11–7.

Schirenbeck A, Bretschneider T, Arasada R, Schleicher M, Faix J. The diaphanous-related formin dDia2 is required for the formation and maintenance of filopodia. Nat Cell Biol 2005;7(6):619–25.

Mizutani K, Miki H, He H, Maruta H, Takenawa T. Essential role of neural Wiskott–Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer Res 2002;62(3):669–74.

Wilkinson S, Paterson HF, Marshall CJ. Cdc42–MRCK and Rho–ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 2005;7(3):255–61.

Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003;5(8):711–9.

Kairouz R, Daly RJ. Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates. Breast Cancer Res 2000;2(3):197–202.

Ying H, Biroc SL, Li W-w, Alicke B, Xuan J-A, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. 2006;5(9):2158–64.

Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360(9334):683–9.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659–72.

Loisel TP, Boujemaa R, Pantaloni D, Carlier MF. Reconstitution of actin-based motility of Listeria and Shigella using pure proteins. Nature 1999;401(6753):613–6.